Date: 2016-04-26
Type of information: Licensing agreement
Compound: Lactobacillus plantarum 299v (LP299V®)
Company: Ipsen (France) Probi (Sweden)
Therapeutic area: Gastrointestinal diseases - Digestive diseases
Type agreement: licensing commercialisation
Action mechanism: live product/probiotic. This dietary supplement contains Lactobacillus plantarum 299v, also called LP299V®, a single species of Lactobacillus that was found by Swedish researchers.
Disease: irritable bowel syndrome
Details: * On April 26, 2016, Ipsen and Probi announced the signature of a license and supply agreement for
the commercialization of Probi’s probiotic strain Lactobacillus plantarum 299v (LP299V®). The agreement covers 18 countries, primarily within EU and emerging markets. This clinically documented probiotic with patents in the gastro-intestinal field is expected to complement Ipsen’s strong medical portfolio in gastroenterology. From Probi’s perspective it could become one of the largest distribution agreements so far, and is of high strategic importance for both companies. Under this new agreement, Probi will supply bulk LP299V® capsules and Ipsen will be responsible
for packaging, marketing and selling the product. The product is planned to be marketed primarily through pharmacies. It is expected to be launched in the first half of 2017 as a food supplement in the European markets, and then, in other key markets such as Russia and China, depending on regulatory approval. The agreement covers in total 18 markets, many with high growth potential, with an option to include additional countries. The product will be marketed under Ipsen’s key brand and Probi’s trademark LP299V®. This agreement marks Ipsen's entry in the field of probiotics.
Financial terms:
Latest news:
